Legal & General Group Plc - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.

Quarter-by-quarter ownership
Legal & General Group Plc ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$3,047,939
-15.7%
67,150
+4.2%
0.00%0.0%
Q2 2023$3,617,382
+30.9%
64,435
+5.5%
0.00%0.0%
Q1 2023$2,763,282
+23.5%
61,094
+11.0%
0.00%0.0%
Q4 2022$2,237,985
-37.1%
55,055
+1.1%
0.00%0.0%
Q3 2022$3,557,000
+5.8%
54,436
-1.6%
0.00%0.0%
Q2 2022$3,361,000
+1.7%
55,306
+5.0%
0.00%0.0%
Q1 2022$3,306,000
-16.1%
52,677
+1.3%
0.00%0.0%
Q4 2021$3,940,000
-26.2%
52,002
+9.0%
0.00%
-50.0%
Q3 2021$5,338,000
-7.8%
47,691
+33.3%
0.00%0.0%
Q2 2021$5,790,000
+43.0%
35,765
+7.6%
0.00%0.0%
Q1 2021$4,050,000
-10.0%
33,235
+13.1%
0.00%0.0%
Q4 2020$4,499,000
+75.7%
29,381
-4.0%
0.00%
+100.0%
Q3 2020$2,560,000
+32.1%
30,599
+16.0%
0.00%0.0%
Q2 2020$1,938,000
+352.8%
26,378
+190.6%
0.00%
Q1 2020$428,000
-79.2%
9,077
-73.2%
0.00%
-100.0%
Q4 2019$2,060,000
+4581.8%
33,830
+3018.0%
0.00%
Q3 2019$44,000
-13.7%
1,0850.0%0.00%
Q2 2019$51,000
+168.4%
1,085
+100.9%
0.00%
Q1 2019$19,000
+26.7%
5400.0%0.00%
Q4 2018$15,000
+87.5%
540
+182.7%
0.00%
Q3 2018$8,000
-27.3%
1910.0%0.00%
Q2 2018$11,0001910.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 3,608,874$160,053,562,00054.44%
Abingworth LLP 1,237,202$54,858,00032.62%
NEA Management Company, LLC 2,090,678$92,722,0004.00%
New Leaf Venture Partners, L.L.C. 444,708$19,723,0003.59%
EcoR1 Capital, LLC 500,000$22,175,0002.00%
ARK Investment Management 1,453,590$64,467,0001.95%
CLOUGH CAPITAL PARTNERS L P 337,731$14,978,0001.41%
Casdin Capital, LLC 220,000$9,757,0001.19%
Valiant Capital Management, L.P. 271,700$12,050,0001.07%
Monashee Investment Management LLC 110,000$4,879,0001.03%
View complete list of CRISPR THERAPEUTICS AG shareholders